Group 1 - The annual "618" shopping festival has begun, with over 13,000 brands achieving doubled sales in the first hour of Tmall's event [1][2] - The beauty and personal care sector has shown remarkable performance in the A-share market, driven by consumption recovery policies and the "618" promotion [1][3] - Analysts suggest that the beauty sector will see structural opportunities due to the "618" event, with a focus on high-quality companies in segments like gold jewelry, medical beauty, offline retail, and pet products [1][4] Group 2 - E-commerce platforms have started their "618" promotions earlier this year, extending the overall duration of the event [2] - Tmall reported that 43 brands achieved over 100 million yuan in sales within the first hour, a more than 50% increase compared to last year [2] - The beauty sector's GMV during the pre-sale period reached between 2.5 billion to 3.5 billion yuan, showing positive year-on-year growth [2] Group 3 - The "618" event has simplified consumer decision-making, enhancing the shopping experience and contributing significantly to brand revenues [3] - The beauty care sector has seen a 4.07% increase in stock prices over the last five trading days, leading among 31 sectors [3] - Analysts recommend focusing on high-growth segments such as gold jewelry, innovative offline retail, and differentiated medical beauty products for investment opportunities [4] Group 4 - The pet economy is gaining attention, with domestic brands benefiting from product innovation and refined marketing strategies [4] - The growth of the pet economy is supported by favorable trends in pet food exports, indicating a positive outlook for related businesses [4]

（原标题：医美市场规模有望增至6000亿！今年已注册1.41万家相关企业） 2.医美相关企业均匀分布在二三线、新一线城市 企查查数据显示，从城市能级分布来看，医美相关现存企业分布较均匀，其中分布在三线城市的医美相 关企业最多，占比22.56%。其次，分布在二线城市、新一线城市的相关企业分别占比21.23%、 20.39%。 3.归属于居民服务、修理和其他服务业的相关企业最多 企查查数据显示，从国标行业来看，归属于居民服务、修理和其他服务业的医美相关企业最多，占比 34.06%。其次，归属于卫生和社会工作的相关企业占比23.14%。此外，医美相关企业也广泛分布在批 发和零售业、租赁和商务服务业、科学研究和技术服务业等国标行业。 近年来，随着社交媒体的普及，美貌得以展现，人们对美的追求愈发多元化。加之政策扶持医美行业规 范化发展与人民可支配收入的提升，美妆、医美等"颜值经济"呈爆发式增长。有业内人士认为，从长期 来看，医美行业依然处于快速成长期，具有巨大的拓展空间。据弗若斯特沙利文预测，到2026年，我国 医美市场规模将达到3998亿元，到2030年有望增至6382亿元，年复合增长率为12.4%。 企查查数据显示 ...

对玻尿酸（透明质酸）、重组胶原蛋白两种流行医美原料的比较，引发了医美巨头华熙生物(688363)对 多家券商研报的公开"声讨"。 深夜发文"声讨" 5月17日晚23时许，华熙生物官方微信号发文《概念总在重演，科技永远向前》，将矛头指向多家券商 研报，相关研报提出胶原蛋白在皮肤修复、抗衰老和副作用等方面强于玻尿酸。 华熙生物在微信文章中表示，2022年开始，随着资本市场不断追求新的公司题材，重组胶原蛋白概念被 看似幸运地选中了。为了营造比透明质酸产业更大的预期，围绕某重组胶原企业的研报中，出现了大量 直接针对中国透明质酸产业的所谓"对比研究"。 包括华泰证券、安信证券等多家券商研报被华熙生物节选发在了上述文章中。华熙生物文章称，这些误 导性"结论"伴随着随后兴起的"玻尿酸过时论"被媒体和自媒体红人广泛传播，形成了资本市场与消费市 场的舆论共振，伤害了经几代人努力的、一个中国优势产业的市场转化基础。 华熙生物表示，透明质酸这一成分及相关产业在近几年资本市场的概念切换中遭遇了谎言与践踏，被描 述为"过时""不如某物质安全""不如某物质更具生物活性""不如某物质具备市场价值"……这些抹黑与受 操控的自媒体及网络上的虚 ...

Core Viewpoint - The article published by Huaxi Biological refutes the notion that hyaluronic acid is "outdated," arguing that this perspective is a product of "impatient capital" attempting to divert attention from the necessary evolution of China's industry [1][2]. Group 1: Industry Analysis - The rise of the "hyaluronic acid is outdated" theory is characterized as a mirage created by certain capital forces, aiming to shift focus towards new investment themes and companies [2]. - Huaxi Biological directly names several brokerage research reports, including those from Western Securities, which have contributed to the spread of misleading comparisons against the hyaluronic acid industry [2][3]. - The misleading conclusions associated with the "hyaluronic acid is outdated" narrative have been widely disseminated by media and influencers, damaging the market foundation of a competitive Chinese industry [3]. Group 2: Company Performance - Huaxi Biological's stock, once reaching a peak of 309.43 yuan per share, has been on a downward trend since July 2021, closing at 50.6 yuan per share on May 19, with a slight increase of 0.22% [3]. - The company staff indicated that stock price fluctuations are influenced by a combination of factors, and they have not yet experienced any legal disputes related to the article [3].

Core Viewpoint - The article discusses the backlash from Huaxi Biological against the notion that hyaluronic acid is "outdated," attributing this perspective to a misleading narrative constructed by "restless capital" and certain brokerage reports [1][4]. Group 1: Market Dynamics - Huaxi Biological published an article refuting the "outdated hyaluronic acid" claim, stating that this narrative undermines the efforts of Chinese scientists and the industry [1]. - The rise of the "outdated hyaluronic acid" theory is seen as a tactic to divert attention from the necessary evolution of the industry, pushing capital towards new themes [4]. Group 2: Brokerage Reports - Multiple brokerage reports, including those from Western Securities, were specifically named by Huaxi Biological for spreading misleading comparisons that favor a collagen company over the hyaluronic acid industry [6]. - Huaxi Biological emphasized that these misleading conclusions have been widely disseminated by media and influencers, creating a negative perception that harms the market foundation of a competitive Chinese industry [6]. Group 3: Financial Performance - Huaxi Biological's stock price peaked at 309.43 CNY per share in July 2021 but has since been on a downward trend, closing at 50.60 CNY on May 19, 2023, reflecting a long-term decline [9][12]. - The company reported a significant drop in revenue from its skin science innovation business, which accounted for nearly half of its revenue, with a year-on-year decline of 31.62% [11]. Group 4: Market Position - Huaxi Biological's market capitalization has decreased from over 1,400 billion CNY at its peak to approximately 244 billion CNY currently [12]. - In contrast, competitors like Juzhi Biological and Jinbo Biological have seen their market values rise significantly, with Juzhi Biological nearing 900 billion HKD and Jinbo Biological's stock price doubling recently [15].

大消费概念持续活跃 丽人丽妆3连板 智通财经5月19日电，午后大消费概念持续活跃，医美、宠物经济方向领涨，丽人丽妆走出3连板，拉芳 家化、源飞宠物涨停，天元宠物、锦波生物、百龙创园、路斯股份股价创出历史新高。消息面上，据粤 开证券统计，国内消费医疗对应万亿级市场规模。医美领域市场规模预计2025年达到3529亿元。 ...

Investment Rating - The report maintains a "Buy" rating for the company [2][8] Core Insights - The company has launched a new product, "Injectable Recombinant Type III Humanized Collagen Gel," utilizing the innovative HiveCOL "honeycomb" collagen tissue network technology, which fills an international gap in the market [5][8] - The product features a dual-core functional area design that is 100% humanized, enhancing its immediate shaping and tissue regeneration capabilities [8] - The company is expected to see significant revenue growth, with projected net profits of 1.148 billion, 1.539 billion, and 1.934 billion yuan for 2025, 2026, and 2027 respectively, reflecting a growth rate of 56.8%, 34.1%, and 25.6% [7][8] Financial Data and Profit Forecast - Total revenue is projected to grow from 1,443 million yuan in 2024 to 3,952 million yuan in 2027, with a compound annual growth rate of approximately 35.0% [7][10] - The gross margin is expected to remain high at around 90% across the forecast period, indicating strong profitability [7][8] - The company's return on equity (ROE) is projected to be 45.8%, 41.6%, and 37.4% for 2025, 2026, and 2027 respectively, showcasing efficient use of equity [7][8]

Core Viewpoint - New Oxygen (SY) reported a strong financial performance for Q1 2025, with revenue reaching 297 million yuan, driven by a significant growth in its light medical beauty chain business, which achieved 98.88 million yuan in revenue, marking a 551% year-on-year increase, indicating a successful strategic transformation [1][4]. Group 1: Financial Performance - In Q1 2025, New Oxygen's revenue was 297 million yuan, with the light medical beauty chain business contributing 98.88 million yuan, a 551% increase year-on-year, achieving a record high for a single quarter [1]. - The chain business has shown continuous growth for six consecutive quarters, with over 92,900 projects redeemed in the quarter, a 989% increase year-on-year, and over 45,500 paid users, an 874% increase [4]. Group 2: Business Strategy and Growth - The company is focusing on its transformation strategy, emphasizing the development of the light medical beauty chain business and investing in vertical integration and business diversification to strengthen its competitive position in the evolving medical beauty sector [1][8]. - New Oxygen has established its first light medical beauty chain store in May 2023, rapidly expanding its presence and becoming a leading player in the industry [1]. Group 3: Customer Satisfaction and Service Model - New Oxygen's service model emphasizes transparency, high quality, and cost-effectiveness, leading to a user satisfaction score of 4.98 out of 5 in Q1 [5]. - The company has expanded its professional doctor team with a 10% acceptance rate, ensuring consistent quality in medical delivery through systematic training and digital management [6]. Group 4: Product and Platform Development - The company has developed a robust upstream product ecosystem, with over 1,500 service institutions and a 14% year-on-year increase in the shipment of its hyaluronic acid brand, exceeding 27,900 units in Q1 2025 [8]. - New Oxygen is transitioning its platform to a "premium mall" model to enhance user experience and conversion rates, with a total transaction value (GMV) of 303 million yuan in Q1 2025 [8].

Investment Rating - The investment rating for the retail industry is "Positive" (maintained) [2] Core Insights - The retail industry is experiencing a significant shift with the 618 e-commerce promotion, characterized by extended activity periods and simplified consumer engagement strategies [27][28] - Domestic beauty brands are showing strong performance, with notable sales figures during the 618 promotion, indicating a trend of rising domestic products [5][32] Summary by Sections Retail Market Review - The retail industry index rose by 1.72% during the week of May 12 to May 16, outperforming the Shanghai Composite Index by 0.96 percentage points [7][16] - The internet e-commerce sector saw the highest growth, with a weekly increase of 5.81%, while the brand cosmetics sector led the year-to-date performance with a 20.30% increase [19][22] 618 Promotion Insights - The 618 e-commerce promotion has begun, with platforms like Taobao, Douyin, and JD extending their promotional periods and simplifying discount mechanisms to enhance consumer experience [27][28] - Sales performance during the promotion has been strong, with Li Jiaqi's live stream achieving a GMV of 25-35 billion yuan on the first day, showcasing the rising dominance of domestic beauty brands [5][32] Investment Recommendations - Focus on high-quality companies in the emotional consumption theme, particularly in sectors like gold jewelry, offline retail, cosmetics, and medical aesthetics [8][35] - Recommended companies include Lao Pu Gold, Chao Hong Ji, Mao Ge Ping, Peiliya, Juzi Biology, and Shangmei Shares, which are expected to benefit from current market trends [38]

创业板指跌幅扩大至1%，上证指数跌0.26%，深证成指跌0.83%。机器人、消费电子、医美、白酒等方 向跌幅居前，沪深京三市下跌个股近3600只。 ...